Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Inovio Pharmaceuticals ( (INO) ) just unveiled an announcement.
On April 1, 2026, Inovio Pharmaceuticals, Inc. notified Oppenheimer & Co. Inc. that it was suspending and terminating the August 13, 2024 at-the-market prospectus tied to its sales agreement for issuing common stock through the firm. The underlying sales agreement with Oppenheimer remains in force, but Inovio will not sell additional shares under this program unless and until it files a new prospectus, temporarily pausing this channel of equity financing.
As of April 1, 2026, Inovio had issued and sold 1,319,644 shares of common stock under the at-the-market program for aggregate gross proceeds of $3.2 million before commissions and expenses. The move effectively caps the current ATM issuance at that level and may signal a shift in the company’s near-term capital-raising strategy, with implications for its liquidity planning and dilution profile for existing shareholders.
The most recent analyst rating on (INO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.
Spark’s Take on INO Stock
According to Spark, TipRanks’ AI Analyst, INO is a Neutral.
The score is held down primarily by very weak financial performance (minimal/collapsing revenue, large losses, and persistent cash burn) and bearish-to-weak technicals (below key moving averages, negative MACD). Offsetting these are earnings-call driven positives from INO-3107 regulatory progress and cost reductions extending runway, though regulatory eligibility risk and shrinking cash remain significant constraints.
To see Spark’s full report on INO stock, click here.
More about Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based medicines and vaccines, with its primary activity centered on issuing and managing common stock to fund operations in the capital markets. The company engages investment banks as sales agents to conduct at-the-market equity offerings, providing financial flexibility to support its research, development and corporate needs.
Average Trading Volume: 1,073,219
Technical Sentiment Signal: Strong Sell
Current Market Cap: $120.2M
For a thorough assessment of INO stock, go to TipRanks’ Stock Analysis page.